Citations

Mayo Clinic

Showing 10 of 108551 citations.

Classifying Germline Sequence Variants in the Era of Next-Generation Sequencing
Baudhuin, Linnea M. , Funke, Birgit , Bean, Lora, Deignan, Joshua L. , Hofherr, Sean, Miller, David T. , Nagan, Narasimhan , Santani, Avni , Saunders, Carol

Clinical Chemistry | February 10, 2016 | Volume: 62 | Issue: 6 | Pages: 799-806

10.1373/clinchem.2015.247874 | PMID 26861553 Get It

PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Incio, João , Tam, Josh, Rahbari, Nuh N. , Suboj, Priya, McManus, Dan T., Chin, Shan M. , Vardam, Trupti D., Batista, Ana , Babykutty, Suboj , Jung, Keehoon , Hato, Tai , Ligibel, Jennifer A. , Krop, Ian E. , Puchner, Stefan B., Schlett, Christopher L. , Hoffmman, Udo, Ancukiewicz, Marek, Shibuya, Masabumi , Carmeliet, Peter , Soares, Raquel , Duda, Dan G. , Jain, Rakesh K., Fukumura, Dai , Khachatryan, Anna , Jain, Rakesh K., Duda, Dan G

Clinical Cancer Research | February 9, 2016 | Volume: 22 | Issue: 12 | Pages: 2993-3004

10.1158/1078-0432.ccr-15-1839 | PMID 26861455 Get It

Abstract Purpose: Obesity promotes pancreatic and breast cancer progression via mechanisms that are poorly understood. Although obesity is associated with increased systemic levels of placental growth factor (PlGF), the role of PlGF in obesity-induced tumor progression is not known. PlGF and its receptor VEGFR-1 have been shown to modulate tumor angiogenesis and promote tumor-associated macrophage (TAM) recruitment and activity. Here, we hypothesized that increased activity of PlGF/VEGFR-1 signaling mediates obesity-induced tumor progression by augmenting tumor angiogenesis and TAM recruitment/activity. Experimental Design: We established diet-induced obese mouse models of wild-type C57BL/6, VEGFR-1 tyrosine kinase (TK)-null, or PlGF-null mice, and evaluated the role of PlGF/VEGFR-1 signaling in pancreatic and breast cancer mouse models and in human samples. Results: We found that obesity increased TAM infiltration, tumor growth, and metastasis in pancreatic cancers, without affecting vessel density. Ablation of VEGFR-1 signaling prevented obesity-induced tumor progression and shifted the tumor immune environment toward an antitumor phenotype. Similar findings were observed in a breast cancer model. Obesity was associated with increased systemic PlGF, but not VEGF-A or VEGF-B, in pancreatic and breast cancer patients and in various mouse models of these cancers. Ablation of PlGF phenocopied the effects of VEGFR-1-TK deletion on tumors in obese mice. PlGF/VEGFR-1-TK deletion prevented weight gain in mice fed a high-fat diet, but exacerbated hyperinsulinemia. Addition of metformin not only normalized insulin levels but also enhanced antitumor immunity. Conclusions: Targeting PlGF/VEGFR-1 signaling reprograms the tumor immune microenvironment and inhibits obesity-induced acceleration of tumor progression. Clin Cancer Res; 22(12); 2993–3004. ©2016 AACR.
Trends in the Utilization of Total Wrist Arthroplasty versus Wrist Fusion for Treatment of Advanced Wrist Arthritis
Marascalchi, Bryan J. , Hinds, Richard , Rizzo, Marco , Capo, John, Melamed, Eitan

Journal of Wrist Surgery | February 9, 2016 | Volume: 05 | Issue: 03 | Pages: 211-216

10.1055/s-0036-1571841 | PMID 27468371 Get It

Screening History Among Women with Invasive Cervical Cancer in an Academic Medical Center: Will We Miss Cancers Following Updated Guidelines?
Nitschmann, Caroline C., May, Taymaa , Mirković, Jelena , Nitschmann, Caroline, Feldman, Sarah

Journal of Women's Health | February 9, 2016 | Volume: 25 | Issue: 8 | Pages: 826-831

10.1089/jwh.2015.5394 | PMID 26859535 Get It

A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin
Sowd, Gregory A. , Serrao, Erik , Wang, Hao , Fadel, Hind J., Poeschla, Eric M. , Engelman, Alan , Wang, Weifeng

Proceedings of the National Academy of Sciences | February 9, 2016 | Volume: 113 | Issue: 8 | Pages: No page available

10.1073/pnas.1524213113 | PMID 26858452 Get It

Significance HIV-1 requires integration for efficient gene expression, and the local chromatin environment significantly influences the level of HIV-1 transcription. Silent, integrated proviruses constitute the latent HIV reservoir. As HIV-1 commandeers cellular factors to dictate its preferred integration sites, these interactions consequentially influence latency. We examined the impact of polyadenylation specificity factor CPSF6, which binds HIV-1 capsid, and the integrase-binding chromatin reader LEDGF/p75 on viral infection and integration site distribution. Integration sites were determined in cells knocked down or knocked out for one or both host factors. Our data indicate that CPSF6 directs HIV-1 to transcriptionally active chromatin, where LEDGF/p75 predominantly directs the positions of integration within genes. These findings clarify the roles of cellular forces that dictate HIV-1 integration preferences and hence virus pathogenesis.
American Thyroid Association Statement on Remote-Access Thyroid Surgery
Bernet, Victor , Fahey, Thomas J. , Kebebew, Electron , Shaha, Ashok, Stack, Brendan C. , Stang, Michael T. , Steward, David L. , Terris, David J. , Berber, Eren

Thyroid | February 9, 2016 | Volume: 26 | Issue: 3 | Pages: 331-337

10.1089/thy.2015.0407 | PMID 26858014 Get It

Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score
Webb, Brandon , Dascomb, Kristin , Stenehjem, Edward , Vikram, Holenarasipur R. , Agrwal, Neera , Sakata, Kenneth K. , Williams, Kathryn , Bagavathy, Kavitha , Mirza, Shireen, Dean, Nathan C. , Webb, Brandon J , Sakata, Kenneth, Vikram, Holenarasipur R. , Bockorny, Bruno , Metersky, Mark L.

Antimicrobial Agents and Chemotherapy | February 9, 2016 | Volume: 60 | Issue: 5 | Pages: 2652-2663

10.1128/aac.03071-15 | PMID 26856838 Get It

ABSTRACT The health care-associated pneumonia (HCAP) criteria have a limited ability to predict pneumonia caused by drug-resistant bacteria and favor the overutilization of broad-spectrum antibiotics. We aimed to derive and validate a clinical prediction score with an improved ability to predict the risk of pneumonia due to drug-resistant pathogens compared to that of HCAP criteria. A derivation cohort of 200 microbiologically confirmed pneumonia cases in 2011 and 2012 was identified retrospectively. Risk factors for pneumonia due to drug-resistant pathogens were evaluated by logistic regression, and a novel prediction score (the drug resistance in pneumonia [DRIP] score) was derived. The score was then validated in a prospective, observational cohort of 200 microbiologically confirmed cases of pneumonia at four U.S. centers in 2013 and 2014. The DRIP score (area under the receiver operator curve [AUROC], 0.88 [95% confidence interval {CI}, 0.82 to 0.93]) performed significantly better ( P = 0.02) than the HCAP criteria (AUROC, 0.72 [95% CI, 0.64 to 0.79]). At a threshold of ≥4 points, the DRIP score demonstrated a sensitivity of 0.82 (95% CI, 0.67 to 0.88), a specificity of 0.81 (95% CI, 0.73 to 0.87), a positive predictive value (PPV) of 0.68 (95% CI, 0.56 to 0.78), and a negative predictive value (NPV) of 0.90 (95% CI, 0.81 to 0.93). By comparison, the performance of HCAP criteria was less favorable: sensitivity was 0.79 (95% CI, 0.67 to 0.88), specificity was 0.65 (95% CI, 0.56 to 0.73), PPV was 0.53 (95% CI, 0.42 to 0.63), and NPV was 0.86 (95% CI, 0.77 to 0.92). The overall accuracy of the HCAP criteria was 69.5% (95% CI, 62.5 to 75.7%), whereas that of the DRIP score was 81.5% (95% CI, 74.2 to 85.6%) ( P = 0.005). Unnecessary extended-spectrum antibiotics were recommended 46% less frequently by applying the DRIP score (25/200, 12.5%) than by use of HCAP criteria (47/200, 23.5%) ( P = 0.004), without increasing the rate at which inadequate treatment recommendations were made. The DRIP score was more predictive of the risk of pneumonia due to drug-resistant pathogens than HCAP criteria and may have the potential to decrease antibiotic overutilization in patients with pneumonia. Validation in larger cohorts of patients with pneumonia due to all causes is necessary.
Impact of an Emergency Department Observation Unit Management Algorithm for Atrial Fibrillation
Bellew, Shawna D., Bremer, Merri L., Kopecky, Stephen L. , Lohse, Christine M. , Munger, Thomas M. , Robelia, Paul M., Smars, Peter A.

Journal of the American Heart Association | February 9, 2016 | Volume: 5 | Issue: 2 | Pages: No page available

10.1161/jaha.115.002984 | PMID 26857070 Get It

Background Atrial fibrillation (AF) is a common, growing, and costly medical condition. We aimed to evaluate the impact of a management algorithm for symptomatic AF that used an emergency department observation unit on hospital admission rates and patient outcomes. Methods and Results This retrospective cohort study compared 563 patients who presented consecutively in the year after implementation of the algorithm, from July 2013 through June 2014 (intervention group), with 627 patients in a historical cohort (preintervention group) who presented consecutively from July 2011 through June 2012. All patients who consented to have their records used for chart review were included if they had a primary final emergency department diagnosis of AF . We observed no significant differences in age, sex, vital signs, body mass index, or CHADS 2 (congestive heart failure, hypertension, age, diabetes mellitus, and prior stroke or transient ischemic attack) score between the preintervention and intervention groups. The rate of inpatient admission was significantly lower in the intervention group (from 45% to 36%; P <0.001). The groups were not significantly different with regard to rates of return emergency department visits (19% versus 17%; P =0.48), hospitalization (18% versus 16%; P =0.22), or adverse events (2% versus 2%; P =0.95) within 30 days. Emergency department observation unit admissions were 40% ( P <0.001) less costly than inpatient hospital admissions of ≤1 day's duration. Conclusions Implementation of an emergency department observation unit AF algorithm was associated with significantly decreased hospital admissions without increasing the rates of return emergency department visits, hospitalization, or adverse events within 30 days.
Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network
Crosslin, DR, Owusu‐Obeng, Aniwaa, Wallace, John R. , Almoguera, Berta , Basford, MA, Bielinski, Suzette J. , Carrell, DS, Connolly, John J. , Doheny, KF, Gallego, CJ, Gordon, Allan , Kirby, Jacqueline, Kitchner, Terrie, Manzi, Shannon , Mejia, A R, Pan, Vivian , Perry, Cassandra, Peterson, JF, Prows, CA, Ralston, James D. , Scott, Stuart A. , Scrol, Aaron, Smith, Maureen E. , Stallings, SC, Veldhuizen, Tamra L., Wolf, W.A., Volpi, Simona , Wiley, Kenneth L , Manolio, Teri A. , Böttinger, Erwin P. , Brilliant, MH, Carey, David J. , Chisholm, Rex L. , Chute, CG, Jl, Haines, Håkonarson, Håkon , Harley, JB, Holm, Ingrid A. , Kullo, IJ, Jarvik, GP, Larson, EB, McCarty, Catherine A. , Williams, MS, Denny, Joshua C. , Rasmussen‐Torvik, LJ, Roden, DM, Ritchie, MD, Rasmussen‐Torvik, Laura J. , Jarvik, Gail P. , Peterson, Josh F. , Bush, William S. , Wallace, J, Crawford, Dana C. , Keating, Brendan J. , Perry, CL, Peterson, JF, Stallings, SC, Li, R, Roden, DM, Ritchie, M.D., Holm, Ingrid A , Hakonarson, Hakon , Denny, Joshua C , Jarvik, Gail P , Bielinski, Suzette , Gordon, Adam S , Connolly, John J , Peterson, Josh F , Scott, Stuart A , Rasmussen-Torvik, Laura J

Clinical Pharmacology & Therapeutics | February 9, 2016 | Volume: 100 | Issue: 2 | Pages: 160-169

10.1002/cpt.350 | PMID 26857349 Get It

Genetic variation can affect drug response in multiple ways, although it remains unclear how rare genetic variants affect drug response. The electronic Medical Records and Genomics (eMERGE) Network, collaborating with the Pharmacogenomics Research Network, began eMERGE‐PGx, a targeted sequencing study to assess genetic variation in 82 pharmacogenes critical for implementation of “precision medicine.” The February 2015 eMERGE‐PGx data release includes sequence‐derived data from ∼5,000 clinical subjects. We present the variant frequency spectrum categorized by variant type, ancestry, and predicted function. We found 95.12% of genes have variants with a scaled Combined Annotation‐Dependent Depletion score above 20, and 96.19% of all samples had one or more Clinical Pharmacogenetics Implementation Consortium Level A actionable variants. These data highlight the distribution and scope of genetic variation in relevant pharmacogenes, identifying challenges associated with implementing clinical sequencing for drug treatment at a broader level, underscoring the importance for multifaceted research in the execution of precision medicine.
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database
Renfro, Lindsay A. , Kerr, David , Gramont, Aimery de , André, Thierry , Guthrie, Katherine A. , Labianca, Roberto , Francini, Guido, Seitz, J. F., O’Callaghan, Chris J. , Twelves, Chris , Haller, Daniel G. , Yothers, Greg , Cheung, Winson Y, de Gramont, Aimery, Saltz, Leonard B. , O'Callaghan, Chris, van Cutsem, Eric, Cheung, Winson Y. , Grothey, Axel , Alberts, Steven R. , Cutsem, Eric Van , Sargent, Daniel J. , André, Thierry , Yothers, Greg

Journal of Clinical Oncology | February 9, 2016 | Volume: 34 | Issue: 11 | Pages: 1182-1189

10.1200/jco.2015.65.1158 | PMID 26858337 Get It

Purpose Factors associated with early mortality after surgery and treatment with adjuvant chemotherapy in colon cancer are poorly understood. We aimed to characterize the determinants of early mortality in a large cohort of colon cancer trial participants. Methods A pooled analysis of 37,568 patients in 25 randomized trials of adjuvant systemic therapy was conducted. Multivariable logistic regression models with several definitions of early mortality (30, 60, and 90 days, and 6 months) were constructed, adjusting for clinically and statistically significant variables. A nomogram for 6-month mortality was developed and validated. Results Median age among patients was 61 years, patient demographics included 54% men and 90% White, 29% and 71% had stage II and III disease, respectively, and 79%, 20%, and 1% had an Eastern Cooperative Oncology Group performance status (PS) of 0, 1, and ≥ 2, respectively. Early mortality was low: 0.3% at 30 days, 0.6% at 60 days, 0.8% at 90 days, and 1.4% at 6 months. Of those patients who died by 6 months post–random assignment, 40% had documented disease recurrence prior to death. Early disease recurrence was associated with a markedly increased risk of death during the first 6 months post-treatment (hazard ratio, 82.6; 95%CI, 66.9 to 102.1). In prognostic analyses, advanced age, male sex, poorer PS, increasing ratio of positive to examined lymph nodes, earlier decade of enrollment, and higher tumor stage and grade predicted a greater likelihood of early mortality, whereas treatment received was not strongly predictive. A multivariable model for 6-month mortality showed strong optimism-adjusted discrimination (concordance index, 0.73) and calibration. Conclusion Early mortality was infrequent but more prevalent in patients with advanced age and a PS of ≥ 2, underscoring the need to carefully consider the risk-to-benefit ratio when making treatment decisions in these subgroups.